Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers.See bulk prices →
Growth hormone axis · Compound
Tesamorelin
Synthetic GHRH analogue, approved in the US as Egrifta for excess abdominal fat in adults with HIV and lipodystrophy, and studied for visceral fat, liver fat and cognition.
Philippines Peptides editorial deskUpdated Trial data checked 23 September 20269 min read
Short answer
Tesamorelin is a growth-hormone-releasing hormone analogue, approved in the US as Egrifta for excess abdominal fat in adults with HIV lipodystrophy. In a phase 3 trial of 412 adults, visceral fat changed by -15.2% on tesamorelin, against +5% on placebo. As of 23 September 2026 it is not registered with FDA Philippines, and prescribing belongs with a licensed Philippine physician.
2:10
Video guide: Tesamorelin in the Philippines: Trials, Status, Sourcing (2:10)Video transcript
Searching for tesamorelin in the Philippines? Here is what it is, what its trials found, and its status here. Tesamorelin is a synthetic analogue of growth hormone releasing hormone. It acts on the pituitary to raise the body's own growth hormone, which raises IGF-1. The US FDA approved it in 2010 as Egrifta, for excess abdominal fat in adults with HIV and lipodystrophy. That approval covers that labelled use only. Its strongest evidence is phase 3 trials in adults with HIV and abdominal fat accumulation. They measured visceral fat, the fat around the abdominal organs, by CT scan. Smaller or earlier trials also looked at fatty liver in HIV, abdominal obesity with reduced growth hormone, and cognition in older adults. Reported side effects include injection site reactions, fluid retention, joint pain, tingling in the hands, and raised blood glucose. The EU application was withdrawn in 2012. In the Philippines, the FDA portal showed no registered tesamorelin product on 23 September. Egrifta is a prescription medicine. Prescribing belongs with a licensed Philippine physician. Tesamorelin is also sold as a research vial: not a registered medicine, not approved for human use, and sold for research only. Our partner and supplier, Primara Labs, lists tesamorelin 10 mg at ₱3,390, or ₱2,076 per vial in a 10 pack. That is about ₱339 per mg, or ₱208 in a 10 pack. Every vial order includes bacteriostatic water, insulin syringes and alcohol pads. Primara stocks in Metro Manila, same day if you order by noon on a weekday. Provinces ship by J&T, and there is a 60-day money-back guarantee. Read the full tesamorelin guide on Philippines Peptides, then see tesamorelin at Primara Labs and order on WhatsApp.
The strongest evidence found for Tesamorelin comes from phase 3 human trials, and every finding below carries its evidence level.
What is Tesamorelin
Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GHRH 1-44). The US FDA approved it on 10 November 2010 as Egrifta for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy; that approval covers the named branded medicine for its labelled use only. In the EU, the Egrifta application was withdrawn on 21 June 2012 and no marketing authorisation was granted. Egrifta is a prescription medicine, and prescribing belongs with a licensed Philippine physician. Browse the full peptide library for related GH compounds.
The strongest evidence for tesamorelin is phase 3 human. Two completed phase 3 placebo-controlled trials in adults with HIV and abdominal fat accumulation (N Engl J Med 2007, n=412; J Acquir Immune Defic Syndr 2010, n=404). The findings of those trials, with their figures, are in the Benefits studied section below. For GLP-1 compounds studied for weight, see the weight loss hub.
Tesamorelin has also been studied in smaller or earlier trials for fatty liver disease in people with HIV, abdominal obesity with reduced growth hormone secretion, and cognition in older adults. The evidence level of each finding is stated where it appears.
How it works
GHRH receptor: in human pharmacology studies, summarised in a 2014 Clinical Pharmacokinetics review, tesamorelin acts on the GHRH receptor in the pituitary to increase basal and pulsatile growth hormone secretion, which in turn raises IGF-1.
Visceral fat: visceral fat is the fat stored around the abdominal organs, as distinct from subcutaneous fat under the skin. In the phase 3 trials in adults with HIV and abdominal fat accumulation, visceral fat was measured by CT scan.
A 20-week phase 2 trial of 152 adults aged 55 to 87 reported a favourable effect on a cognitive composite, mostly executive function; two later trials in other groups found no significant effect. Source: Arch Neurol 2012
Liver fat reduction
Small human studies
A 12-month randomised, placebo-controlled trial of 61 people with HIV and fatty liver disease, phase not stated, found liver fat fraction fell 4.1 percentage points more on tesamorelin than on placebo. Source: Lancet HIV 2019
Side effects reported
No human trial in the datasets reports adverse-event rates for Tesamorelin, whose human evidence is limited to phase 3 human (10 completed randomised trials identified). Without controlled data, its safety in people is unknown rather than established.
What the trials found
In Tesamorelin phase 3 (Falutz, NEJM 2007), a 26-week phase 3 trial of 412 adults with HIV and abdominal fat accumulation (86% men), visceral adipose tissue changed by -15.2% on the 2 mg arm, against 5% on placebo. Source · Registry
Completed trials of Tesamorelin with a reported result
Trial and population
n
Weeks
Outcome
Change by arm
Comparator
Source
Tesamorelin phase 3 (Falutz, NEJM 2007) · Phase 3Adults with HIV and abdominal fat accumulation (86% men)
No registered drug product found on the FDA verification portal.
US FDA
Approved for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.Drugs@FDA: Egrifta (BLA022505, approved 10 November 2010). The approval covers the named branded medicine for its labelled use only, never a vial of the same substance sold for research use.
European Medicines Agency
Not approvedThe application for Egrifta (EMEA/H/C/002427) was withdrawn on 21 June 2012; no marketing authorisation was granted.
How Philippine registration and prescription rules work, and what an unregistered product is under the law, is covered in the regulation hub, and every compound's status side by side is on the status page. This is general information, not legal advice.
Who should not use Tesamorelin
Everything above is research framing. For the material itself, our partner and supplier lists tesamorelin 10mg at Primara Labs for ₱3,775 (₱3,390 with 10% off), from stock inside the Philippines.
FAQ
How does tesamorelin differ from CJC-1295?
Both are analogues of growth hormone-releasing hormone that act on the GHRH receptor in the pituitary. The strongest evidence for tesamorelin is phase 3 human, in adults with HIV and abdominal fat accumulation. The strongest evidence for CJC-1295 is small human studies. No trial comparing the two appears in the datasets this site draws on.
What is the difference between tesamorelin and HGH?
Tesamorelin is a GHRH analogue: it acts on the pituitary to increase the body's own growth hormone secretion, basal and pulsatile, which raises IGF-1. Recombinant human growth hormone is growth hormone itself, given directly. No trial comparing the two appears in the datasets this site draws on.
What evidence exists for tesamorelin?
The evidence level for tesamorelin is phase 3 human. Completed human randomised controlled trials identified: 10 (Completed human RCTs identified and screened in Europe PMC). Studied for: Excess visceral fat in people with HIV on antiretroviral therapy, fatty liver disease in HIV, abdominal obesity with reduced growth hormone secretion, and cognition in older adults. Key source: Falutz J et al. N Engl J Med 2007.
Is tesamorelin registered in the Philippines?
FDA Philippines status: No registered drug product found on the FDA verification portal. US FDA: Approved for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. EMA: Not approved. Prescribing belongs with a licensed Philippine physician. The regulatory status page sets out the status of every compound in the regulatory dataset.
Where to get Tesamorelin in the Philippines
Readers who want the 90 days mapped out before they order start with the Longevity Manila protocol planner, which sets one goal, sequences the compounds behind it, and hands the list to our partner and supplier, Primara Labs.
The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
